The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of fixed-dose rate gemcitabine, bevacizumab, and concurrent 30 gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.
George Van Buren
No relevant relationships to disclose
George Van Buren
Disclosure not yet available
Ramesh K. Ramanathan
No relevant relationships to disclose
Alyssa M Krasinskas
Research Funding - Genentech
Ryan Smith
No relevant relationships to disclose
Gerard J. Abood
No relevant relationships to disclose
Yongli Shuai
Research Funding - Genentech
Douglas M. Potter
Research Funding - Genentech
Nathan Bahary
No relevant relationships to disclose
Barry C. Lembersky
No relevant relationships to disclose
Amer H Zureikat
No relevant relationships to disclose
David L. Bartlett
No relevant relationships to disclose
Herbert Zeh
No relevant relationships to disclose
Arthur J Moser
Research Funding - Genentech